These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27890944)

  • 1. Role of high-sensitivity C-reactive protein measurements in HIV patients.
    Vishwanath A; Quaiser S; Khan R
    Indian J Sex Transm Dis AIDS; 2016; 37(2):123-128. PubMed ID: 27890944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein among people living with HIV on highly active antiretroviral therapy: a systemic review and meta-analysis.
    Mabhida SE; Mchiza ZJ; Mokgalaboni K; Hanser S; Choshi J; Mokoena H; Ziqubu K; Masilela C; Nkambule BB; Ndwandwe DE; Kengne AP; Dludla PV
    BMC Infect Dis; 2024 Feb; 24(1):160. PubMed ID: 38308222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of highly active antiretroviral therapy (HAART) and menopause on risk of progression of cervical dysplasia in human immune-deficiency virus- (HIV-) infected women.
    Kim SC; Messing S; Shah K; Luque AE
    Infect Dis Obstet Gynecol; 2013; 2013():784718. PubMed ID: 24453469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased endothelial biomarkers are associated with HIV antiretroviral therapy and C-reactive protein among a African rural population in Limpopo Province, South Africa.
    Hanser S; Mphekgwana PM; Moraba MM; Erasmus L; van Staden M
    Front Public Health; 2022; 10():980754. PubMed ID: 36407976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.
    Green TN; Archary M; Gordon ML; Padayachi N; Lie Y; Anton ED; Reeves JD; Grobler A; Bobat R; Coovadia H; Ndung'u T
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):324-32. PubMed ID: 21819257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and menopause: a review.
    Kojic EM; Wang CC; Cu-Uvin S
    J Womens Health (Larchmt); 2007 Dec; 16(10):1402-11. PubMed ID: 18062755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era.
    Ramana KV; Sabitha V; Rao R
    J Clin Diagn Res; 2013 Jul; 7(7):1332-5. PubMed ID: 23998059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-virological status and its associated factors among HIV-positive patients receiving highly active antiretroviral therapy at delgi primary hospital, northwest Ethiopia, 2020/2021: A cross-sectional study.
    Kiros T; Taye A; Workineh L; Eyayu T; Damtie S; Hailemichael W; Tiruneh T
    Heliyon; 2022 Aug; 8(8):e10169. PubMed ID: 36033289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings.
    Mahajan AP; Hogan JW; Snyder B; Kumarasamy N; Mehta K; Solomon S; Carpenter CC; Mayer KH; Flanigan TP
    J Acquir Immune Defic Syndr; 2004 May; 36(1):567-75. PubMed ID: 15097299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?
    Beach MC; Keruly J; Moore RD
    J Gen Intern Med; 2006 Jun; 21(6):661-5. PubMed ID: 16808754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
    Mosam A; Shaik F; Uldrick TS; Esterhuizen T; Friedland GH; Scadden DT; Aboobaker J; Coovadia HM
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):150-7. PubMed ID: 22395672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.
    Regidor DL; Detels R; Breen EC; Widney DP; Jacobson LP; Palella F; Rinaldo CR; Bream JH; Martínez-Maza O
    AIDS; 2011 Jan; 25(3):303-14. PubMed ID: 21192231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers.
    Phoswa WN; Naicker T; Ramsuran V; Moodley J
    Inflamm Res; 2019 Jan; 68(1):47-57. PubMed ID: 30276649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
    Lange CG; Woolley IJ; Brodt RH
    Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
    McCabe CJ; Goldie SJ; Fisman DN
    PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy in a resource-deprived setting.
    Nugent J; Edmonds A; Lusiama J; Thompson D; Behets F;
    Pediatr Infect Dis J; 2014 Nov; 33(11):1148-55. PubMed ID: 24945879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferritin levels during structured treatment interruption of highly active antiretroviral therapy.
    Boom J; Kösters E; Duncombe C; Kerr S; Hirschel B; Ruxrungtham K; de Mast Q; Kosalaraksa P; Ulbolyam S; Jupimai T; Ananworanich J;
    HIV Med; 2007 Sep; 8(6):388-95. PubMed ID: 17661847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.
    Yamashita TE; Phair JP; Muñoz A; Margolick JB; Detels R; O'Brien SJ; Mellors JW; Wolinsky SM; Jacobson LP
    AIDS; 2001 Apr; 15(6):735-46. PubMed ID: 11371688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.